Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00571389
Other study ID # BioCytics 0001
Secondary ID WIRB Protocol #
Status Recruiting
Phase
First received
Last updated
Start date November 2007
Est. completion date February 2025

Study information

Verified date April 2022
Source BioCytics, Inc.
Contact John Powderly, MD
Phone 704-947-6599
Email jpowderly@carolinabiooncology.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers. The preliminary objective of this study is aimed at selecting PD-1+ and CTLA4+ T cells and other cellular fractions from peripheral blood of cancer patients and healthy volunteers by using specific conjugated antibodies, evaluating their functional ex vivo anti-tumor cytotoxicity against targeted autologous tumor cells.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date February 2025
Est. primary completion date February 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 5 Years and older
Eligibility Inclusion Criteria for Biospecimen(s) collection: Cancer Cohort Inclusion Criteria: 1. Male or Female Adult = 18 years of age. 2. Histological diagnosis of any solid tumor type and at any stage of disease progression including in the neoadjuvant/presurgical setting, adjuvant setting, or considered in remission. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 3 (see Appendix 2) and an estimated life expectancy of at least 3 months. 4. Subject or subject's legal representative provides written informed consent. 5. Negative serology screening test for HIV, Hepatitis B surface antigen, and Hepatitis C antibody, or negative reflex PCR test result for HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) 6. Additional eligibility criteria need to be met for leukapheresis collection: - ECOG Performance Status of 0 or 1 (see Appendix 2) - WBC =2000/µL - Neutrophils =1000/µL - Platelets =100x103/µL - Hemoglobin =9 g/dL - Creatinine =2.5 x ULN - AST =2.5 x ULN without, and = 5 x ULN with hepatic metastases - Bilirubin =2 x ULN (except patients with Gilbert's syndrome, who must have total bilirubin = 3.0 mg/dL) - Negative urine pregnancy test for women of childbearing potential Healthy Volunteer Cohort Inclusion Criteria: 1. Male or Female Adult = 18 years of age. ? Pediatric healthy volunteers from 5-17 years of age, with suspected or confirmed COVID-19 diagnosis by laboratory test will be eligible to participate in minimally invasive biospecimen collection procedures, as long as written parental consent has been obtained, and if applicable and technologically able, child assent. Minimally invasive biospecimen collection procedures allowed for pediatric participation include swabs (nasal, NP and OP), microcapillary sampling, and saliva or urine collection. 2. Healthy volunteers are eligible, including the following: - History of autoimmune disease or inflammatory disorder considered clinically stable by the Principal Investigator or treating physician's discretion. - Suspected or diagnosed COVID-19 disease by laboratory test, whether in the acute, sub-acute or convalesced state. - Employees of the study site(s) or BioCytics, as long as fulfilment of inclusion criteria 3.c is obtained. 3. Subject or subject's legal representative provides written informed consent. 4. Negative serology screening test for HIV, Hepatitis B surface antigen, and Hepatitis C antibody, or negative reflex PCR test result for HIV, HBV, and HCV. 5. Additional eligibility criteria need to be met for leukapheresis collection: - Must be = 18 years of age. - WBC =2000/µL - Neutrophils =1000/µL - Platelets =100x103/µL - Hemoglobin =9 g/dL - Creatinine =2.5 x ULN - AST =2.5 x ULN - Bilirubin =2 x ULN (except patients with Gilbert's syndrome, who must have total bilirubin = 3.0 mg/dL) - Negative urine pregnancy test for women of childbearing potential 2.3.4. Exclusion Criteria 1. Subjects with active infection requiring therapy (fever, localizing source) will be excluded until the infection resolves. a. This excludes subjects with suspected or confirmed COVID-19 by laboratory test while in the acute and sub-acute phase of viremia. 2. Underlying medical condition that, in the Principal Investigator's or treating oncologist's opinion, will obscure the interpretation of the patient's safety. 3. Confirmed positive reflex PCR test result for HIV, Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV).

Study Design


Locations

Country Name City State
United States Carolina BioOncology Institute Huntersville North Carolina

Sponsors (1)

Lead Sponsor Collaborator
BioCytics, Inc.

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Terminated NCT04551885 - FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Phase 1
Completed NCT05054348 - First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Recruiting NCT06088004 - Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05055609 - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors Phase 1
Completed NCT04020185 - Safety and Efficacy Study of IMSA101 in Refractory Malignancies Phase 1/Phase 2
Withdrawn NCT05071846 - MVX-ONCO-2 in Advanced Solid Tumors Phase 1
Recruiting NCT05607199 - A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics Phase 1
Active, not recruiting NCT04552288 - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Phase 2
Active, not recruiting NCT06026254 - A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial Phase 1
Recruiting NCT06032845 - Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11) Phase 2
Recruiting NCT06144671 - GT201 Injection For The Treatment Of Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06398418 - R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors Phase 1
Recruiting NCT05276284 - Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy Phase 1/Phase 2
Recruiting NCT04121442 - Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04221204 - A Monotherapy in Subjects With Advanced Solid Tumors Phase 1
Terminated NCT03992326 - Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors Phase 1
Terminated NCT05435339 - A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy Phase 1/Phase 2
Recruiting NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Recruiting NCT06075849 - Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent Phase 1

External Links